EU One Plan on AMRBrussels, 29th of June 2017. The European Commission adopted a new EU action plan on AMR, officially titled ‘Communication from the Commission to the Council and the European Parliament: A European One Health Action Plan against Antimicrobial Resistance (AMR)’.

This new One Health action plan is motivated by the need to fight against AMR, with the EU supporting Member States through EU added value actions, leading and contributing towards this global issue. Its overarching goal is to counteract emerging resistances, their spread and ensure that there continues to be availability of effective treatment for infections in humans and animals. It provides a framework for continued, coherent and more extensive action to tackle AMR.

TBEC, RUK and GHA each submitted to the EC consultation on the AMR Action Plan in April. Highlights of the new One Health action plan are presented below:

Interesting mentions:

    • “Special attention will be given to the WHO priority list of pathogens as well as to tuberculosis, HIV/AIDS, malaria and neglected infectious diseases.”
    • “AMR in bacteria linked to numerous common infections (e.g. urinary tract infections, pneumonia, tuberculosis and gonorrhoea) have been observed in all WHO regions. Resistance to antivirals, such as those used to treat HIV, is also increasing.”
    • “More research is also needed to advance the repurposing of old antimicrobials, improving their activity and to develop new combination therapies, including those to treat multidrug resistant tuberculosis (MDR-TB).”

The EC will work towards:

Supporting research into the development of new economic models:

  • develop, with the support of the OECD, a model aimed at helping Member States to assess the economic burden of AMR imposed on people and to estimate the cost-effectiveness of their national policies to reduce it;
  • increase the evidence base for understanding the societal costs and benefits of different strategies for fighting AMR, including understanding factors that influence the uptake of interventions such as novel diagnostics or preventive measures;
  • analyse EU regulatory tools and incentives – in particular orphan and paediatric legislation – to use them for novel antimicrobials and innovative alternative medicinal products (e.g. vaccines, antibacterial, antifungal, antiviral agents) that currently do not generate sufficient returns on investment;
  • encourage Member States to explore results and recommendations of EU research projects on new economic business models.

Continue reading…

Below you will find links to the new action plan and further resources:

Action Plan
Action Plan in all EU languages
Summary Action Plan Factsheet
Press Release
Questions & Answers
Results of the open public consultation
Guidelines on prudent use of antimicrobials in human health
Video in 23 languages


flag_yellow_low

This blog is the product of an activity that has received funding under an operating grant from the European Union’s Health Programme (2014-2020).

The content of this blog represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.